Cargando…
Clinical practice of hepatitis B screening in patients starting with chemotherapy: A survey among Dutch oncologists
OBJECTIVE: Screening for hepatitis B virus (HBV) before chemotherapy is recommended by international guidelines; still, the HBV screening rate is low, and patients remain at risk for HBV reactivation (HBVr). Because HBVr is a serious and preventable condition, we conducted a survey to evaluate the s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285452/ https://www.ncbi.nlm.nih.gov/pubmed/34310787 http://dx.doi.org/10.1111/ecc.13495 |
_version_ | 1784747783680425984 |
---|---|
author | Leber, Karin Otten, Hans‐Martin J. M. M. B. Brandjes, Dees P. M. Claassen, Mark A. A. Lauw, Fanny N. |
author_facet | Leber, Karin Otten, Hans‐Martin J. M. M. B. Brandjes, Dees P. M. Claassen, Mark A. A. Lauw, Fanny N. |
author_sort | Leber, Karin |
collection | PubMed |
description | OBJECTIVE: Screening for hepatitis B virus (HBV) before chemotherapy is recommended by international guidelines; still, the HBV screening rate is low, and patients remain at risk for HBV reactivation (HBVr). Because HBVr is a serious and preventable condition, we conducted a survey to evaluate the screening behaviour of oncologists in the Netherlands. METHODS: We conducted an anonymous digital survey by email to all practicing medical oncologists. The surveys were sent in two session, the first one in 2017 and the second one in 2019. Questions included HBV screening procedures, reasons for screening and experience with HBVr. RESULTS: Among the 110 respondents, 29 (27%) followed a standardised protocol. Overall, 13 (12%) oncologists screened all patients, 76 (70%) only screened patients they considered as high risk and 19 (18%) did not screen anyone. Fourteen percent of the respondents experienced a HBVr in one of their patients. CONCLUSION: This survey suggests that universal HBV screening is not common practice and usually patients considered as at risk for HBVr are screened, while this group is not always properly identified. Introduction of a national protocol for HBV screening and adjustment of the Dutch oncology guidelines might contribute to a reduction of HBVr during chemotherapy. |
format | Online Article Text |
id | pubmed-9285452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92854522022-07-18 Clinical practice of hepatitis B screening in patients starting with chemotherapy: A survey among Dutch oncologists Leber, Karin Otten, Hans‐Martin J. M. M. B. Brandjes, Dees P. M. Claassen, Mark A. A. Lauw, Fanny N. Eur J Cancer Care (Engl) Original Articles OBJECTIVE: Screening for hepatitis B virus (HBV) before chemotherapy is recommended by international guidelines; still, the HBV screening rate is low, and patients remain at risk for HBV reactivation (HBVr). Because HBVr is a serious and preventable condition, we conducted a survey to evaluate the screening behaviour of oncologists in the Netherlands. METHODS: We conducted an anonymous digital survey by email to all practicing medical oncologists. The surveys were sent in two session, the first one in 2017 and the second one in 2019. Questions included HBV screening procedures, reasons for screening and experience with HBVr. RESULTS: Among the 110 respondents, 29 (27%) followed a standardised protocol. Overall, 13 (12%) oncologists screened all patients, 76 (70%) only screened patients they considered as high risk and 19 (18%) did not screen anyone. Fourteen percent of the respondents experienced a HBVr in one of their patients. CONCLUSION: This survey suggests that universal HBV screening is not common practice and usually patients considered as at risk for HBVr are screened, while this group is not always properly identified. Introduction of a national protocol for HBV screening and adjustment of the Dutch oncology guidelines might contribute to a reduction of HBVr during chemotherapy. John Wiley and Sons Inc. 2021-07-26 2021-11 /pmc/articles/PMC9285452/ /pubmed/34310787 http://dx.doi.org/10.1111/ecc.13495 Text en © 2021 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Leber, Karin Otten, Hans‐Martin J. M. M. B. Brandjes, Dees P. M. Claassen, Mark A. A. Lauw, Fanny N. Clinical practice of hepatitis B screening in patients starting with chemotherapy: A survey among Dutch oncologists |
title | Clinical practice of hepatitis B screening in patients starting with chemotherapy: A survey among Dutch oncologists |
title_full | Clinical practice of hepatitis B screening in patients starting with chemotherapy: A survey among Dutch oncologists |
title_fullStr | Clinical practice of hepatitis B screening in patients starting with chemotherapy: A survey among Dutch oncologists |
title_full_unstemmed | Clinical practice of hepatitis B screening in patients starting with chemotherapy: A survey among Dutch oncologists |
title_short | Clinical practice of hepatitis B screening in patients starting with chemotherapy: A survey among Dutch oncologists |
title_sort | clinical practice of hepatitis b screening in patients starting with chemotherapy: a survey among dutch oncologists |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285452/ https://www.ncbi.nlm.nih.gov/pubmed/34310787 http://dx.doi.org/10.1111/ecc.13495 |
work_keys_str_mv | AT leberkarin clinicalpracticeofhepatitisbscreeninginpatientsstartingwithchemotherapyasurveyamongdutchoncologists AT ottenhansmartinjmmb clinicalpracticeofhepatitisbscreeninginpatientsstartingwithchemotherapyasurveyamongdutchoncologists AT brandjesdeespm clinicalpracticeofhepatitisbscreeninginpatientsstartingwithchemotherapyasurveyamongdutchoncologists AT claassenmarkaa clinicalpracticeofhepatitisbscreeninginpatientsstartingwithchemotherapyasurveyamongdutchoncologists AT lauwfannyn clinicalpracticeofhepatitisbscreeninginpatientsstartingwithchemotherapyasurveyamongdutchoncologists |